Natco Pharma Vizag facility begins production
The Visakhapatnam facility was a part of the Special Economic Zone (SEZ) and intended to cater primarily to the U.S. and other international markets, Natco Pharma said.
Hyderabad: Natco Pharma Limited on Thursday announced the commencement of commercial operations by its Finished Dosage Formulations (FDF) facility in Visakhapatnam, which is a key part of its capacity expansion plans.
The facility was a part of the Special Economic Zone (SEZ) and intended to cater primarily to the U.S. and other international markets, a company release here said.
The Vizag facility is a key part of Natco's capacity expansion plans for its pipeline of products and diversification into different geographies.
From the capability perspective, this facility will focus mostly on oral solid dosages (tablets and capsules), including a cytotoxic block for products in the oncology segment, the city-based drugmaker said.
An application with the U.S. Food and Drug Administration (USFDA) is already filed for site transfer of the first product and for a regulatory audit, it added.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here